Devyser Diagnostics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Jan Wahlstrom
Chief executive officer
SEK 2.9m
Total compensation
| CEO salary percentage | 48.00% |
| CEO tenure | 1yr |
| CEO ownership | 0.09% |
| Management average tenure | 3.8yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Narrative Update • Aug 04
DVYSR: Italian Tender And New Chimerism Assay Will Support Future Upside
Analysts have reduced their price target for Devyser Diagnostics to SEK 97.58 from SEK 120.86, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News for Devyser Diagnostics Devyser Diagnostics launched the One Lambda Devyser Chimerism Plus assay for chimerism analysis after allogeneic hematopoietic stem cell transplantation, focused on reducing testing errors and improving laboratory efficiency.Narrative Update • Jul 20
DVYSR: Italian Tender Wins Will Support Long-Term Genetic Diagnostics Momentum
Analysts have trimmed their price target for Devyser Diagnostics to SEK120.86 from SEK156.12, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E that point to a more conservative valuation framework. What's in the News Devyser Diagnostics launched One Lambda Devyser Chimerism Plus, a next generation solution for chimerism analysis following allogeneic hematopoietic stem cell transplantation.Analysis Article • Jul 20
Some Devyser Diagnostics AB (publ) (STO:DVYSR) Analysts Just Made A Major Cut To Next Year's Estimates
The latest analyst coverage could presage a bad day for Devyser Diagnostics AB (publ) ( STO:DVYSR ), with the analysts...
New Narrative • Jul 18
R&D And Partner Risks Will Pressure Margins Before Long-Term Genetics Demand Emerges
Catalysts About Devyser Diagnostics Devyser Diagnostics develops and sells genetic testing kits and services for hereditary disease and transplantation applications. What are the underlying business or industry changes driving this perspective?Analysis Article • May 04
Devyser Diagnostics' (STO:DVYSR) Earnings Are Of Questionable Quality
Devyser Diagnostics AB (publ) ( STO:DVYSR ) just reported some strong earnings, and the market reacted accordingly with...Analysis Article • Apr 30
Devyser Diagnostics AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a good week for Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders, because the company has just...Analysis Article • Apr 18
We Think Devyser Diagnostics (STO:DVYSR) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • Feb 15
Earnings Update: Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders are probably feeling a little disappointed, since its shares...Analysis Article • Nov 08
Earnings Miss: Devyser Diagnostics AB (publ) Missed EPS And Analysts Are Revising Their Forecasts
It's been a sad week for Devyser Diagnostics AB (publ) ( STO:DVYSR ), who've watched their investment drop 17% to kr108...Analysis Article • Nov 04
Are Investors Undervaluing Devyser Diagnostics AB (publ) (STO:DVYSR) By 21%?
Key Insights The projected fair value for Devyser Diagnostics is kr156 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Jul 25
Devyser Diagnostics AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders of Devyser Diagnostics AB (publ) ( STO:DVYSR ) will be pleased this week, given that the stock price is up...Analysis Article • Jul 23
Revenues Tell The Story For Devyser Diagnostics AB (publ) (STO:DVYSR) As Its Stock Soars 31%
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shares have continued their recent momentum with a 31% gain in the last...Analysis Article • May 10
Optimistic Investors Push Devyser Diagnostics AB (publ) (STO:DVYSR) Shares Up 27% But Growth Is Lacking
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders are no doubt pleased to see that the share price has bounced...Analysis Article • May 02
Devyser Diagnostics AB (publ) (STO:DVYSR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
The analysts might have been a bit too bullish on Devyser Diagnostics AB (publ) ( STO:DVYSR ), given that the company...Analysis Article • Apr 09
Companies Like Devyser Diagnostics (STO:DVYSR) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analysis Article • Feb 17
Devyser Diagnostics AB (publ) (STO:DVYSR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Last week saw the newest full-year earnings release from Devyser Diagnostics AB (publ) ( STO:DVYSR ), an important...Analysis Article • Jun 14
Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts
Shareholders in Devyser Diagnostics AB (publ) ( STO:DVYSR ) may be thrilled to learn that the analysts have just...Analysis Article • Mar 20
Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company
The Devyser Diagnostics AB (publ) ( STO:DVYSR ) share price has done very well over the last month, posting an...Analysis Article • Feb 23
Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a pretty great week for Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders, with its shares surging 16...Analysis Article • Feb 22
Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Dec 09
Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shares have had a really impressive month, gaining 28% after a shaky period...Analysis Article • Aug 30
These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts
Today is shaping up negative for Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders, with the analysts delivering...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | SEK 15m |
| Dec 31 2025 | SEK 3m | SEK 1m | -SEK 8m |
Compensation vs Market: Jan's total compensation ($USD307.45K) is about average for companies of similar size in the Swedish market ($USD386.13K).
Compensation vs Earnings: Insufficient data to compare Jan's compensation with company performance.
CEO
Jan Wahlstrom (59 yo)
1yr
Tenure
SEK 2,916,600
Compensation
Mr. Jan Wahlstrom is Chief Executive Officer of Devyser Diagnostics AB (publ) from August 4, 2025. Mr. Wahlstrom was Chief Executive Officer of Mabtech AB from May 2022 until 2025. He serves as Independent...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1yr | SEK 2.92m | 0.092% SEK 946.8k | |
| Chief Financial Officer | 5.6yrs | no data | 0.035% SEK 363.0k | |
| Chief Scientific Officer | 3.6yrs | no data | 0.0018% SEK 18.4k | |
| Chief Human Resource Officer | 3.9yrs | no data | 0.0012% SEK 12.2k | |
| VP & GM of Devyser US | 3.8yrs | no data | no data |
3.8yrs
Average Tenure
47.5yo
Average Age
Experienced Management: DVYSR's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 4.9yrs | SEK 200.00k | 0.015% SEK 149.7k | |
| Independent Director | 2.3yrs | SEK 200.00k | 0.62% SEK 6.4m | |
| Chairman | 16.6yrs | SEK 400.00k | 24.74% SEK 255.3m | |
| Director | 5.6yrs | SEK 200.00k | 0.26% SEK 2.7m | |
| Independent Director | 1.3yrs | SEK 100.00k | no data |
4.9yrs
Average Tenure
57yo
Average Age
Experienced Board: DVYSR's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/20 00:14 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Devyser Diagnostics AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Erik Hultgård | DNB Carnegie |
| Ludvig Lundgren | Nordea Markets |